SELLAS Life Sciences Announces Appointment of Gene Mack as Chief Financial Officer & Treasurer
April 20 2018 - 8:45AM
SELLAS Life Sciences Group Inc., (Nasdaq:SLS) (SELLAS), a
clinical-stage biopharmaceutical company focused on novel cancer
immunotherapies for a broad range of cancer indications, today
announced the appointment of Gene Mack as Chief Financial Officer
and Treasurer.
“We are delighted to welcome Gene to our executive team. He has
a proven track record of leveraging his deep expertise in corporate
finance and strategy to help companies develop important therapies
for patients and deliver significant value for shareholders,” said
Angelos Stergiou, M.D., ScD h.c., President and Chief Executive
Officer of SELLAS. “That experience, coupled with his leadership
ability, will be of great value to SELLAS as we continue to advance
our pipeline of novel cancer immunotherapies and expand our
management team.”
Mr. Mack joins SELLAS having served as a consulting chief
financial officer for a number of private and publicly traded
biotechnology and pharmaceutical companies, developing strategy and
leading management of all company finance, accounting, and treasury
functions, most recently with Nicox, SA. Prior to consulting, Mr.
Mack held finance and business development positions at Ascendia
Pharmaceuticals and Edge Therapeutics. Over the past 5 years, Mr.
Mack has raised over $300 million in equity and debt financing
while also advising on numerous successful M&A and product
licensing transactions. Mr. Mack also spent over 13 years as a
senior publishing analyst in life sciences equity research at Brean
Capital, Lazard, and HSBC Capital Markets. Mr. Mack began his
career conducting clinical research at Columbia University College
of Physicians and Surgeons. Mr. Mack holds a B.S. in Biochemistry
and an M.B.A. in Finance, both from Fordham University.
“With a diverse, late-stage pipeline of immunotherapies, SELLAS
has the potential to bring innovative new treatments to patients
with life-threatening diseases,” said Mr. Mack. “I am thrilled to
join SELLAS’ experienced leadership team and look forward to
contributing to the company’s growth at this exciting time.”
Interim Chief Financial Officer Aleksey Krylov will remain with
SELLAS until July 15th in order to facilitate the transition. “I
would like to thank Aleksey for his service as Interim Chief
Financial Officer. He has achieved multiple milestones for SELLAS,
including the completion of our reverse merger and the closing of
our recent strategic financing,” said Dr. Stergiou.
About SELLAS Life Sciences Group
SELLAS is a clinical-stage biopharmaceutical company focused on
novel cancer immunotherapeutics for a broad range of cancer
indications. SELLAS’ lead product candidate, galinpepimut-S (GPS),
is licensed from Memorial Sloan Kettering Cancer Center and targets
the Wilms Tumor 1 (WT1) protein, which is present in an array of
tumor types. GPS has potential as a monotherapy or in
combination to address a broad spectrum of hematologic malignancies
and solid tumor indications. SELLAS has Phase 3 clinical
trials planned (pending funding availability) for GPS in two
indications, acute myeloid leukemia (AML) and malignant pleural
mesothelioma (MPM) and is also developing GPS as a potential
treatment for multiple myeloma and ovarian cancer. SELLAS
plans to study GPS in up to four additional indications.
SELLAS has received Orphan Drug designations from the U.S. Food
& Drug Administration (FDA), as well as the European Medicines
Agency, for GPS in AML and MPM; GPS also received Fast Track
designation for AML and MPM from the FDA.
For more information on SELLAS, please visit
www.sellaslifesciences.com.
Investor Contact:Will O’ConnorStern Investor
Relations, Inc.212-362-1200ir@sellaslife.com
David Moser, JDSELLAS Life Sciences Group,
Inc.813-864-2571info@sellaslife.com
Source: SELLAS Life Sciences Group, Inc.
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Aug 2024 to Sep 2024
SELLAS Life Sciences (NASDAQ:SLS)
Historical Stock Chart
From Sep 2023 to Sep 2024